Erste Asset Management’s Krystal Biotech KRYS Stock Holding History

Erste Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.29M	Hold	8,700	–	–	0.03%	331
2026 Q1	$2.15M	Buy	8,700 +3,000	+53%	+$798K	0.02%	355
2025 Q4	$1.45M	Sell	5,700 -12,500	-69%	-$2.63M	0.01%	391
2025 Q3	$3.22M	Hold	18,200	–	–	0.03%	303
2025 Q2	$2.53M	Hold	18,200	–	–	0.02%	366
2025 Q1	$3.35M	Hold	18,200	–	–	0.04%	256
2024 Q4	$2.9M	Hold	18,200	–	–	0.04%	283
2024 Q3	$3.22M	Hold	18,200	–	–	0.04%	275
2024 Q2	$3.33M	Hold	18,200	–	–	0.04%	264
2024 Q1	$3.23M	Hold	18,200	–	–	0.04%	265
2023 Q4	$2.33M	Buy	18,200 +12,800	+237%	+$1.42M	0.03%	278
2023 Q3	$637K	Hold	5,400	–	–	0.01%	383
2023 Q2	$625K	Hold	5,400	–	–	0.01%	399
2023 Q1	$428K	Hold	5,400	–	–	0.01%	436
2022 Q4	$431K	Hold	5,400	–	–	0.01%	436
2022 Q3	$381K	Hold	5,400	–	–	0.01%	449
2022 Q2	$349K	Hold	5,400	–	–	0.01%	464
2022 Q1	$361K	Buy	+5,400	New	+$337K	0.01%	463

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Erste Asset Management's KRYS Position: Q2 2026 in Review

Erste Asset Management held its Krystal Biotech (KRYS) position steady in Q2 2026 at 8,700 shares worth $3.29M. The position accounts for 0.03% of the portfolio, ranked #331.

Erste Asset Management first reported a position in KRYS in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.35M in Q1 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Erste Asset Management held 8,700 shares of Krystal Biotech worth $3.29M as of Q2 2026.
Erste Asset Management left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up 0.03% of Erste Asset Management's portfolio in Q2 2026, its #331 holding.
Erste Asset Management first reported a position in Krystal Biotech in Q1 2022 and has held it in 18 quarters since.
Erste Asset Management's Krystal Biotech position peaked at $3.35M in Q1 2025.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.